Blautia wexlerae: A Metabolically Relevant Gut Species, Explained

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

Measures the abundance of Blautia wexlerae in your gut microbiome to reveal potential microbial imbalances. Detecting low or altered levels—which studies link to metabolic and inflammatory risks such as obesity, insulin resistance, and gut inflammation—may help you take targeted diet or lifestyle steps to lower those risks.

Read more →

Understand what your gut health results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

A targeted look at a metabolic-relevant gut species

A blautia wexlerae test is a targeted analysis of your stool that quantifies one species within your gut microbiome. It uses DNA sequencing methods — typically 16S rRNA profiling or shotgun metagenomics — to detect and estimate the relative abundance of B. wexlerae among your intestinal microbes. Some labs also apply qPCR for added specificity. The result reflects a snapshot of your current microbial ecosystem, not a permanent trait, because gut communities shift with diet, medications, stress, illness, and travel.

Why focus on this organism? Blautia wexlerae is part of a broader microbial network that helps process carbohydrates and fibers into short-chain metabolites that influence gut barrier integrity, local inflammation, and metabolic signaling. Its levels can mirror how your gut environment is functioning today — digestion, immune tone, and metabolic flexibility all intersect here. Research on this species is evolving, and while early findings are promising, interpretation should be paired with your symptoms, diet history, and other biomarkers to avoid overreading a single microbe.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Why a single species earns its own reading

Testing for Blautia wexlerae within a gut microbiome panel helps connect microscopic activity to real-world health outcomes. This species has been associated with short-chain fatty acid production, metabolic regulation, and modulation of immune tone—areas that affect digestion, energy, and inflammatory balance. When levels fall outside expected ranges, it can hint at microbial imbalances (dysbiosis) that contribute to symptoms like bloating, irregular stools, or fatigue. Testing becomes especially informative after antibiotics, significant dietary changes, or periods of high stress, when microbial stability is most likely to shift.

Zooming out, gut microbiome testing offers a system-wide lens on health, revealing how shifts in microbial balance can ripple through metabolism, inflammation, and even mood. Tracking Blautia wexlerae and other core genera over time helps show whether interventions—like adjusting fiber intake, trying specific probiotics, or improving sleep—are supporting microbial diversity and resilience. The goal isn’t to chase a single “ideal” microbe, but to understand your gut’s unique pattern so you can make evidence-informed choices for long-term well-being.

Reading the abundance number

Results typically show your B. wexlerae as a relative abundance (a percentage or fraction of total microbial DNA) and often a percentile versus a reference population. There isn’t a single “universal optimal” number — healthy microbiomes vary widely by diet, geography, and genetics. In general, balanced microbiomes lean toward higher diversity and a richer representation of beneficial, fiber-loving species. If your B. wexlerae sits near the lower end compared to peers, it may point to a gut environment that’s producing fewer fermentation-derived metabolites that support barrier function and calm immune signaling. If it’s high, interpretation depends on the broader microbial context and your symptoms.

When B. wexlerae is present within a balanced community, it often coincides with efficient fermentation, short-chain fatty acid generation, a tighter gut barrier, and a quieter inflammatory tone — the kind of milieu that supports steadier post-meal glucose and metabolic flexibility. That said, the same percentage can mean different things in different diets. Someone eating a high-fiber, plant-forward pattern may “host” B. wexlerae alongside multiple cooperative species, while a low-fiber pattern can make any single microbe look more prominent without reflecting robust function.

If your result suggests relative depletion, it’s a clue to examine the ecosystem inputs that shape this species: fermentable fibers, polyphenols, meal patterns, sleep, and stress. Mechanistically, when carbohydrate reaches the colon, microbes ferment it into metabolites that feed colon cells, modulate immune cells, and interact with hormone pathways that influence appetite and glucose — a natural counterpoint to the GLP‑1 buzz you hear about from drugs like Ozempic, though the magnitude and reliability are not the same and human data are still growing. If your level is elevated, it can reflect a community shift that may normalize as diet diversity and overall microbial diversity improve. Either way, interpretation should be anchored to your symptoms, history, and broader labs, not a single cut-point.

. Early experimental data in animals support mechanistic plausibility, yet large, long-term human trials are still needed to define clinical thresholds and outcomes.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What this reading can and can't tell you

Big picture: your blautia wexlerae test becomes most actionable when viewed alongside your full microbiome profile and key biomarkers of inflammation and metabolism. Over time, trend lines — not single snapshots — reveal how your body responds to changes in fiber variety, meal timing, movement, sleep quality, and stress load. Use this result as a conversation starter with your clinician or dietitian to personalize strategies that support digestion, energy, and long-term metabolic resilience while staying aligned with current evidence.

Frequently Asked Questions

References

  1. Hosomi K, Saito M, Park J, Murakami H, Shibata N, Ando M, Nagatake T, Konishi K, Ohno H, Tanisawa K, Mohsen A, Chen YA, Kawashima H, Natsume-Kitatani Y, Oka Y, Shimizu H, Furuta M, Tojima Y, Sawane K, ... Kunisawa J (2022). Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. *Nature Communications*, *13*, 4477. https://doi.org/10.1038/s41467-022-32015-7
  2. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell*, *165*(6), 1332-1345. https://doi.org/10.1016/j.cell.2016.05.041
  3. Durazzi F, Sala C, Castellani G, Manfreda G, Remondini D, De Cesare A (2021). Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota. *Scientific Reports*, *11*, 3030. https://doi.org/10.1038/s41598-021-82726-y
  4. Lynch SV, Pedersen O (2016). The human intestinal microbiome in health and disease. *The New England Journal of Medicine*, *375*(24), 2369-2379. https://doi.org/10.1056/NEJMra1600266
  5. Porcari S, Mullish BH, Asnicar F, Ng SC, Zhao L, Hansen R, O'Toole PW, Raes J, Hold G, Putignani L, Gasbarrini A, Segata N, Cammarota G (2025). International consensus statement on microbiome testing in clinical practice. *The Lancet Gastroenterology & Hepatology*, *10*(2), 154-167. https://doi.org/10.1016/S2468-1253(24)00311-X

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey